Policy Position

CHA Submits Energy and Commerce Committee Statement on Oversight of the 340B Drug Pricing Program

Children's Hospital Association urges the committee to work with provider stakeholders to enhance the effectiveness and integrity of the program for children's health.

Published July 09, 2024 | 1 min. read
DOWNLOAD

The House Energy and Commerce Subcommittee on Oversight and Investigations held a hearing titled, “Oversight of the 340B Drug Pricing Program.” The discussion focused on the 340B drug pricing program’s impact on patients, the health care system, and potential reforms.

Children's Hospital Association submitted a statement expressing our strong support for the program as well as our concerns about the 340B ACCESS Act and urged the committee to work with provider stakeholders to further enhance the effectiveness and integrity of the program. 

Speech bubble

Contact Us

For more information, connect with us.

Related Content

How CHA Mitigated a Cancer Drug Shortage’s Impact

The recent shortage highlighted pediatrics’ vital need for ifosfamide.

Sep. 03, 2026

A New Blueprint for a Resilient Pediatric Supply Chain

An unprecedented public-private collaboration shows promise in mitigating drug shortages.

March 24, 2026

Protecting 340B Allows Hospitals to Invest Millions in Children's Health

A recent assessment showed children’s hospitals participating in the federal drug pricing discount program save hundreds of millions annually — and invest even more into their communities.

March 03, 2026